13 assets in Ulcerative Colitis

Therapeutic assets addressing Ulcerative Colitis, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Oxygen Ulcerative Colitis	Jay C. Buckey Jr.	P4	BB (64)
Mirikizumab Ulcerative Colitis	Eli Lilly and Company	P3	B (60)
Nivolumab Ulcerative Colitis	Diwakar Davar	P2	B (60)
Pembrolizumab Ulcerative Colitis	Diwakar Davar	P2	B (60)
Tirzepatide Ulcerative Colitis	Eli Lilly and Company	P3	B (60)
Amelenodor Ulcerative Colitis	AbbVie	P2	CCC (53)
Atorvastatin Ulcerative Colitis	Northwestern University	P2	CCC (53)
Tamuzimod Ulcerative Colitis	Oppilan Pharma Ltd	P2	CCC (53)
Vancomycin Ulcerative Colitis	Tampere University Hospital	P2	CCC (53)
gsk3888130b Ulcerative Colitis	GlaxoSmithKline	P1	CC (47)
Cabozantinib Ulcerative Colitis	National Cancer Institute (NCI)	P1	CC (43)
Ipilimumab Ulcerative Colitis	National Cancer Institute (NCI)	P1	CC (43)